Spruce Street Capital LP Makes New Investment in Enanta Pharmaceuticals, Inc. $ENTA

Spruce Street Capital LP acquired a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 1,088,731 shares of the biotechnology company’s stock, valued at approximately $15,873,698. Enanta Pharmaceuticals comprises about 0.0% of Spruce Street Capital LP’s investment portfolio, making the stock its 11th largest holding. Spruce Street Capital LP owned about 3.74% of Enanta Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. AQR Capital Management LLC grew its stake in shares of Enanta Pharmaceuticals by 674.7% during the first quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock valued at $1,971,000 after buying an additional 311,010 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Enanta Pharmaceuticals by 50.2% in the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock valued at $7,435,000 after purchasing an additional 449,945 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Enanta Pharmaceuticals by 5.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company’s stock worth $720,000 after buying an additional 6,549 shares during the last quarter. Invesco Ltd. grew its position in Enanta Pharmaceuticals by 4.3% in the 2nd quarter. Invesco Ltd. now owns 62,884 shares of the biotechnology company’s stock valued at $475,000 after acquiring an additional 2,607 shares in the last quarter. Finally, Marshall Wace LLP lifted its stake in Enanta Pharmaceuticals by 0.8% in the second quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock valued at $6,482,000 after buying an additional 6,522 shares during the last quarter. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ:ENTA traded down $0.27 on Friday, hitting $13.53. 95,435 shares of the company’s stock were exchanged, compared to its average volume of 198,580. The stock has a market capitalization of $393.99 million, a price-to-earnings ratio of -5.61 and a beta of 0.98. Enanta Pharmaceuticals, Inc. has a 12 month low of $7.05 and a 12 month high of $17.15. The business’s 50 day simple moving average is $13.57 and its two-hundred day simple moving average is $13.48.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%.The company had revenue of $14.36 million for the quarter, compared to analysts’ expectations of $16.76 million. Equities analysts forecast that Enanta Pharmaceuticals, Inc. will post -2.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ENTA. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd. Wall Street Zen downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.50.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.